Genomtec

What Genomtec does

Genomtec S.A. is a publicly traded Polish molecular diagnostics company (WSE main market ticker: GMT) founded in 2016 in Wrocław by scientists specializing in molecular biology, microfluidics, and photonics. The company develops a proprietary microfluidic lab-on-chip platform for point-of-care genetic testing, built on its SNAAT® (Specific Nucleic Acid Amplification Technology) isothermal amplification method and a patented non-contact heating and temperature detection system. Its core product, the Genomtec ID analyzer, is designed to deliver molecular-grade diagnostic results in approximately 15 minutes without laboratory infrastructure, targeting clinics, pharmacies, hospital emergency departments, and diagnostic laboratories.

The product portfolio spans the Genomtec ID Respiratory Panel 5-Plex (CE-IVD certified in June 2022 as the only 5-plex respiratory panel in Europe), SARS-CoV-2 RT-LAMP kits including the world's first CE-IVD certified saliva-direct test, and the OncoSNAAT® oncology diagnostics platform for cancer mutation detection. Revenue in 2023 was PLN 1,000, reflecting pre-commercialization status. Commercialization occurs through exclusive distribution agreements with Atropos Ltd. (Greece) and ForLab SA (broader Europe), a Taiwan partner for Asia, and direct sales to reference laboratories such as DCM DOLMED S.A. The company holds 9 granted patents and 26+ pending applications globally, with ISO 13485 quality certification and an IP portfolio independently valued at EUR 191.336 million by Dennemeyer Consulting.

Genomtec operates as a clinical-stage platform whose primary monetization path is shifting toward M&A: it has engaged Clairfield Partners since November 2022 to advise on strategic partnerships, licensing, or sale of its technology platforms. In March 2025 the company established two wholly-owned special purpose vehicles — GMT ID SA (Genomtec ID infectious disease platform) and GMT Genomics SA (OncoSNAAT oncology project) — to enable separate transactions. Funding has come primarily from non-dilutive Polish and EU grants (NCBiR ~EUR 1.6M in 2020, PARP ~EUR 5M in 2023) and equity raises including a 2020 IPO (PLN 8M+), a PLN 11M investment from 5HT Family Foundation in March 2025, and a EUR 2.6M raise in June 2026 bringing total available funding above EUR 9 million.

Name

Genomtec

Legal name

GENOMTEC S.A.

Website

https://genomtec.com

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Genomtec S.A. is a Polish molecular diagnostics company (WSE: GMT) developing the Genomtec ID point-of-care lab-on-chip platform using proprietary SNAAT isothermal amplification and non-contact heating technology for rapid infectious disease and oncology testing in clinics, pharmacies, and laboratories.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics Devices and Consumables

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Molecular diagnostics
• Point-of-care testing
• Lab-on-chip technology
• Isothermal amplification
• Infectious disease diagnostics

Headquarters

HQ city

Wroclaw

HQ country

Poland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Genomtec ID Analyzer Device Sales: Sale of portable molecular diagnostics hardware (Genomtec ID analyzers). Pilot production initiated January 2022 with first 15 devices manufactured in UK in collaboration with CDMO partner.
2. Diagnostic Test Kits and Consumables: Sale of single-use diagnostic test kits including RP5-PLEX respiratory panel, SARS-CoV-2 RT-LAMP kits (EvaGreen, Duo Kit, Direct-RT-LAMP), saliva collection and transport kits.
3. Technology Licensing: Strategic partnerships and licensing arrangements for Genomtec ID platform and OncoSNAAT technology through M&A process with global IVD companies.
4. Government Research Grants: R&D project funding from Polish public sources (PARP, NCBiR, EU programs) supporting development of diagnostic technologies. Grants are non-dilutive funding.

Pricing tiers

Go-to-market motion3 records

Distribution channels7 records

Marketing channels8 records

Core offering

Genomtec develops and manufactures the Genomtec ID, a portable molecular diagnostics platform based on proprietary SNAAT isothermal amplification technology and microfluidic lab-on-chip technology, paired with CE-IVD certified diagnostic test panels for point-of-care infectious disease detection (respiratory 5-plex) and oncology applications. The company sells the hardware analyzer (pilot production launched 2022) along with consumable diagnostic kits, and pursues technology licensing partnerships with global IVD companies.

Product overview

Genomtec is an innovative medical technology company that has developed a mobile molecular diagnostic platform called Genomtec ID, which uses proprietary microfluidic lab-on-chip technology with patented non-contact heating and detection systems, along with the SNAAT isothermal amplification method. The product portfolio includes the core Genomtec ID analyzer platform, diagnostic panels (Respiratory Panel 5-Plex for 5 pathogens and OncoSNAAT for cancer mutations), laboratory diagnostic kits (RT-LAMP Duo Kit and Direct-RT-LAMP Kit for SARS-CoV-2 testing from saliva), and related accessories. The company transitioned from primarily infectious disease focus to also include oncology diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

• Genomtec ID: Mobile platform for point-of-care genetic diagnostics enabling rapid molecular testing at clinics, pharmacies, and hospital emergency departments without need for complex laboratory infrastructure
• Genomtec Tumor (OncoSNAAT)
• Genomtec SARS-CoV-2 EvaGreen
• Genomtec RT-LAMP Duo Kit
• Genomtec RT-LAMP Direct
• SNAAT

Products and services

• Genomtec ID Mobile molecular diagnostic platform (lab-on-chip) for point-of-care genetic testing. Enables rapid detection of infectious diseases and oncology applications at clinics, pharmacies, and hospital emergency departments without requiring complex laboratory infrastructure.
• Genomtec ID Respiratory Panel 5-Plex (RP5-PLEX) CE-IVD certified diagnostic panel for use on the Genomtec ID platform that simultaneously detects 5 viruses and bacteria causing respiratory tract infections in a single test. The only panel of its kind in Europe.
• Genomtec Tumor / OncoSNAAT Oncology diagnostics platform for cancer mutation detection using isothermal nucleic acid amplification techniques and lab-on-chip solutions. Targets clinical oncology settings requiring rapid genetic mutation detection for cancer diagnosis and treatment personalization.
• Genomtec SARS-CoV-2 EvaGreen RT-LAMP Duo Kit CE-IVD certified two-gene rapid genetic test for SARS-CoV-2 detection designed to detect all known variants including British, South African, Brazilian, and Brittany variants. Catalog product GA00B.
• Genomtec SARS-CoV-2 EvaGreen Direct-RT-LAMP Kit World's first CE-IVD certified genetic diagnostic test for SARS-CoV-2 detection directly from saliva samples without nucleic acid extraction. Enables patient-friendly sample collection without nasopharynx swabbing.
• Saliva Sample Collection and Transport Kit CE-IVD certified kit for collection and transport of saliva samples for genetic testing. Supports the Direct-RT-LAMP saliva workflow.

Quantifiable outcome

• Rapid genetic diagnosis in approximately 15 minutes versus hours for traditional PCR lab testing
• +4 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature7 records

Partnerships

Eleven partnerships are on record, tiered minor, major and core.

• Taiwan Distribution PartnerminorChannel Partner/ Reseller/ Distributor · 1 August 2022Partner appointed to help with identification and qualification of new local business prospects and opportunities for Genomtec ID platform in Taiwan (R.O.C.). Part of Asian market development strategy.
• ForLab SAmajorChannel Partner/ Reseller/ Distributor · 1 June 2022Additional European distributor for Genomtec ID portable testing platform and RP5-PLEX panel. Second European distribution partner complementing Atropos Ltd. relationship. Expands geographic coverage across European markets.
• UK CDMO PartnercoreImplementation/ SI/ Consulting Partner · 1 June 2022Conditional agreement with UK-based Contract Development and Manufacturing Organization (CDMO) for manufacturing Genomtec ID device. Pilot production of first 15 analyzers conducted in UK in collaboration with this partner. Critical for device commercialization.
• Atropos Ltd.majorChannel Partner/ Reseller/ Distributor · 1 April 2022Exclusive distribution agreement for Genomtec ID genetic testing platform and Respiratory Panel 5-Plex test in Greece. Atropos is a specialist distributor of molecular biology solutions with established market position. Distribution to begin following regulatory approval.
• Prof. Krishnendu ChakrabartyminorOthers · 1 July 2021Appointed to Scientific Advisory Board. Professor at Duke University, holder of 18 US patents, recipient of Japan Society for Promotion of Science fellowship. Research on microfluidic biochips licensed to Advanced Liquid Logic, Illumina, GenMark, and Baebies Inc.
• Cellgen Molecular Pathology Center (NZOZ Aurimed)minorStrategic or Co-development Partner · 1 May 2021Agreement for additional comparative study of Genomtec Direct-RT-LAMP saliva test against RT-PCR reference method. Clinical data enriching validation research at Central Clinical Hospital enabling EU market authorization.
• DCM DOLMED S.A.minorStrategic or Co-development Partner · 1 April 2021Lower Silesian Medical Center DOLMED S.A. becoming reference laboratory for Genomtec products. Agreement for genetic diagnostic laboratory utilizing RT-LAMP technique for SARS-CoV-2 testing using Genomtec SARS-CoV-2 EvaGreen RT-LAMP CE-IVD Duo-Kit.
• Synektik S.A.minorChannel Partner/ Reseller/ Distributor · 1 July 2020Non-exclusive commercial cooperation agreement for distribution of Genomtec SARS-CoV-2 tests in Poland. Includes active marketing of GNT (SNAAT) technology across all Synektik channels. Partnership extended marketing reach into Polish laboratory and healthcare facility networks.
• AstraZeneca Pharma PolandminorStrategic or Co-development Partner · 1 July 2019Letter of intent for potential commercial use of Genomtec technology for diagnostics and personalization of treatment for patients with non-small cell lung cancer (NSCLC), which accounts for approximately 80% of all lung cancer cases.
• Politechnika Wrocławska (Wroclaw University of Science and Technology)minorStrategic or Co-development Partner · 1 April 2018Subcontractor selected through tender for R&D services to develop, design, and manufacture prototype disposable Lab-On-Chip card. Partnership leveraging university's microfluidic and materials science expertise.
• AmplusminorStrategic or Co-development Partner · 1 June 2017Pilot implementation partnership in Pilot Maker programme for quick identification of environmental contamination on agricultural areas using Genomtec mobile diagnostic solutions and SNAAT detection technology. Leading Polish producer and distributor of fresh fruit and vegetables.

Scale indicators17 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• QIAGEN: Broad incumbent in molecular diagnostics and sample-preparation technologies. QIAGEN provides PCR-based and isothermal amplification reagents, automated systems, and oncology companion diagnostics - spanning multiple applications where Genomtec competes, including HPV testing and oncology mutation detection.
• Abbott (Molecular Diagnostics): Broad incumbent offering the ID NOW rapid molecular platform for point-of-care infectious disease testing. Abbott's established global distribution and broader IVD portfolio make it a key competitor for Genomtec in POC respiratory and infectious disease markets.
• QuidelOrtho: Broad incumbent in rapid immunoassay and molecular diagnostics, including Sofia and Savanna platforms for point-of-care testing. Comparable to Genomtec in addressing decentralized clinical settings with rapid turnaround diagnostic solutions.
• Hologic (Panther / Aptima): Broad incumbent in molecular diagnostics for women's health, infectious disease, and oncology. Panther Fusion system targets hospital labs with multiplex respiratory panels comparable to Genomtec RP5-PLEX.
• Roche Diagnostics: Broad incumbent with cobas Liat PCR system for point-of-care molecular testing and a deep oncology diagnostics franchise. Competes across Genomtec's infectious disease and oncology verticals with much greater scale, menu breadth, and global commercial reach.

Emerging players

• Bosch Healthcare Solutions (Vivalytic): Emerging player offering the Vivalytic point-of-care molecular diagnostics platform, with cartridge-based multiplex testing for respiratory and other infectious diseases. Comparable to Genomtec ID in form factor, POC positioning, and target customers.
• Talis Biomedical: Emerging player that developed the Talis One point-of-care molecular diagnostics platform for rapid infectious disease testing, including respiratory panels. Comparable technology positioning to Genomtec ID though commercially constrained.
• Credo Diagnostics Biomedical: Emerging player developing portable PCR-based molecular diagnostic devices (VitaPCR) for point-of-care use. Comparable to Genomtec in POC platform positioning, menu focus, and target customer segments.

Direct peers

• BioMérieux (BioFire): Direct peer in syndromic molecular diagnostics. BioFire FilmArray panels detect multiple respiratory pathogens simultaneously in a single cartridge, directly comparable to Genomtec's RP5-PLEX. Both target the decentralized hospital/clinical market with multiplex panels.
• Cepheid (Danaher): Direct peer in point-of-care molecular diagnostics. Cepheid's GeneXpert system is the established market leader in rapid molecular testing for infectious diseases including respiratory pathogens, using cartridge-based PCR. Competes with Genomtec ID in the same POC clinical setting with a similar menu-expansion strategy.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genomtec